Investigating new peptides and small molecules that target signaling proteins in cells
Official title: Peptides and Small-molecules Targeting Signaling Proteins and Protein-Protein Interfaces
Funded at University of New Hampshire · NIH-10876324 · Data updated 2026-11-12
This study is exploring how tiny molecules can interact with important proteins in our cells to help improve treatments for diabetes and some cancers, making it easier for doctors to find new ways to help patients feel better.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of New Hampshire NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project start | September 15, 2020 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $364,862 |
| NIH project number | 5R35GM138217-05 |
| Project ID | NIH-10876324 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with diabetes or cancers that may benefit from targeted therapies aimed at cell signaling pathways.
✕Less likely to help
Patients with conditions unrelated to cell signaling or those not responsive to peptide-based therapies may not benefit from this research.
What this research studies
This research focuses on understanding how certain peptides and small molecules can interact with cell-surface receptors and intracellular proteins that are crucial for cellular signaling. By combining computational studies with experimental data, the project aims to identify novel peptide mimetics and analogues that can target specific receptor proteins, particularly those related to insulin and G-protein coupled receptors. The goal is to develop new therapeutic agents that can modulate these signaling pathways, potentially leading to better treatments for conditions like diabetes and certain cancers.
Why it matters
Potential benefit: If successful, this research could lead to the development of innovative therapies that improve treatment options for patients with diabetes and cancers.
How similar studies have gone: Previous research has shown promise in targeting cell signaling pathways with peptide-based therapies, indicating a potential for success in this novel approach.
Where this research is happening
-
University of New Hampshire
Durham, United States Active
Researchers
- Principal investigator: Vashisth, Harish — University of New Hampshire
- Study coordinator: Vashisth, Harish
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.